Overview

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

Status:
COMPLETED
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the ability of HT-6184 to decrease inflammation and pain in patients after third molar removal. The main question it aims to answer are: * Does HT-6184 decrease inflammation in patients after third molar removal? * Does HT-6184 decrease pain in patients after third molar removal? Participants will be asked to do the following during the clinical trial: * Take a single oral dose of HT-6184 or placebo * Allow a oral surgeon remove their third molar teeth * Blood draws on 5 occurrences * Rate their pain intensity * Attend two follow-up appointments on day 1 and day 2 after third molar removal * Participate in one follow-up phone call 5-7 days after third molar removal
Phase:
PHASE2
Details
Lead Sponsor:
Halia Therapeutics, Inc.